Hikma Pharmaceuticals (LON:HIK) Rating Lowered to Neutral at JPMorgan Chase & Co.

JPMorgan Chase & Co. cut shares of Hikma Pharmaceuticals (LON:HIK – Get Rating) to a neutral rating in a research note published on Wednesday, Marketbeat Ratings reports. They currently have GBX 1,900 ($23.91) price target on the stock, down from their prior price target of GBX 2,900 ($36.49).

Several other equities analysts have also issued reports on HIK. Barclays reissued an overweight rating and issued a GBX 2,500 ($31.46) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 24th. Morgan Stanley reissued an equal weight rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, May 11th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of GBX 2,444.29 ($30.76).

Hikma Pharmaceuticals stock opened at GBX 1,688.50 ($21.25) on Wednesday. The stock’s 50 day moving average is GBX 1,924.78 and its 200 day moving average is GBX 2,046.94. The company has a debt-to-equity ratio of 34.29, a current ratio of 2.06 and a quick ratio of 1.31. The firm has a market cap of £3.75 billion and a P/E ratio of 11.79. Hikma Pharmaceuticals has a one year low of GBX 1,631.50 ($20.53) and a one year high of GBX 2,703 ($34.01).

In other news, insider Sigurdur Olafsson sold 27,498 shares of the business’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of GBX 1,988 ($25.02), for a total transaction of £546,660.24 ($687,882.52). Also, insider Douglas Hurt acquired 1,500 shares of the firm’s stock in a transaction dated Thursday, March 3rd. The shares were purchased at an average price of GBX 1,954 ($24.59) per share, with a total value of £29,310 ($36,881.84).

Hikma Pharmaceuticals Company Profile (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

See Also